Login to Your Account


Ophthamology specialist Ocular Therapeutix Inc. downsized its initial public offering (IPO), raising $65 million through the sale of 5 million shares sold at $13 each instead of the company's desired $14 to $16.

Gene therapy specialist Applied Genetic Technologies Corp. (AGTC) banked new funds with a stock sale of 2 million shares priced at $15 each, for a net haul of $30 million, following by several months an initial public offering (IPO) that pulled down $50 million.
Synlogic Inc. tucked a $29.4 million series A into its belt as it aims at the nexus of synthetic biology and the microbiome with the development of therapeutic microbes. Atlas Venture and New Enterprise Associates led the round, which will enable Cambridge, Mass.-based Synlogic to build out its microbial engineering platform and advance its preclinical pipeline through clinical proof of concept in several applications.
More FINANCINGS Headlines

Cast Your Vote

Has biotech’s bubble burst?: